chrisvoncsefalvay/vaers-outcomes huggingface dataset:
10 hours after injection began running a fever of 102, chilling, achy, headache. Treated with tylenol and lasted about 5 hours. Felt very tired and achy for the next 12-14 hours. Returned to work two days after feeling fine.
Began to have body aches mid-morning that lasted all day.  Late morning had chills.  Had fever (101.5) and chills into the evening of 12/6/16 and lasted until morning of 12/7/16.  12/7/16 had a very swollen and painful lymph node / gland under left arm.  Had Tdap on my left are on 12/5/16.
Violently ill; Congestion; Coughing; vomiting; Little discomfort on arm; Felt tired; This spontaneous case was reported by a consumer and describes the occurrence of DISCOMFORT (Little discomfort on arm), MALAISE (Violently ill), NASAL CONGESTION (Congestion), COUGH (Coughing) and FATIGUE (Felt tired) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037A21B) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event.    On 25-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Mar-2021, the patient experienced DISCOMFORT (Little discomfort on arm) and FATIGUE (Felt tired). On an unknown date, the patient experienced MALAISE (Violently ill), NASAL CONGESTION (Congestion), COUGH (Coughing) and VOMITING (vomiting). At the time of the report, DISCOMFORT (Little discomfort on arm), MALAISE (Violently ill), NASAL CONGESTION (Congestion), COUGH (Coughing), FATIGUE (Felt tired) and VOMITING (vomiting) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medications information were provided . No medical history
Product had undergone TE and it was administered after the TE; No additional AE; This spontaneous report was received from a Medical Assistant and refers to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not provided.  On an unknown date, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) injection, lot #w039294, expiration date: 11-DEC-2024, administered for prophylaxis (anatomical location, strength, and route of administration were not provided) and before administration the product undergone temperature excursion (TE) (product storage error). No additional adverse events (AE).
CLOT IN LUNGS; This spontaneous report received from a pharmacist concerned a 58 year old male. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included unknown. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported and batch number: 043A21A expiry: UNKNOWN) dose was not reported, administered on 06-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 12-MAY-2021, the patient experienced clot in lungs, and was hospitalized (date unspecified). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from clot in lungs. This report was serious (Hospitalization Caused / Prolonged).; Sender's Comments: V0 : 20210522762 - Covid-19 vaccine ad26.cov2.s - CLOT IN LUNGS . This event(s) is considered unassessable. The event(s) has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
Very red hot to touch swollen arm, pain in joints, slight fever, breathing problems, wheezing.  Was sent to hospital, put on Lasix, antibiotic and breathing treatments.
Cancer; This spontaneous case was reported by a consumer and describes the occurrence of NEOPLASM MALIGNANT (Cancer) in a patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced NEOPLASM MALIGNANT (Cancer) (seriousness criteria death and medically significant). The reported cause of death was Cancer. It is unknown if an autopsy was performed.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NEOPLASM MALIGNANT (Cancer) to be related.    No concomitant medication was reported. Suspect product dosage text was reported as unknown. It was reported that cancer rates for jabbed Moderna Cancer patients was up 300 percent. No treatment medication was reported. This case contains information about 10th patient out of 25 patients. Company comment- This is a fatal spontaneous case concerning a patient of unknown gender and age with no medical history reported who experienced the serious (death and medically significant) unexpected event of neoplasm malignant. A dose of mRNA-1273.222 (Original/Omicron BA.4/5) vaccine was administered. Temporal association cannot be assessed due to lack of information on onset date of the event and vaccination date. It is unknown if autopsy was performed. Reporter stated that vaccine caused cancer in 25 patients who are friends of her. No further details were provided for medical review. The benefit-risk relationship of mRNA-1273.222 (Original/Omicron BA.4/5) vaccine is not affected by this report.   This case was linked to US-MODERNATX, INC.-MOD-2023-735987 (E2B Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-735987:Master case, Patient 1; Reported Cause(s) of Death: Cancer
Information has been received from a pharmacist concerning a patient who on an unspecified date was vaccinated with a dose of ZOSTAVAX (Merck) (Lot # not reported) and developed hives 2-3 weeks after receiving the vaccine. The patient's outcome was not reported. It was unknown if the patient sought medical attention. Additional information has been requested.
Foggy head/cloudy head. Really severe weakness in my legs. I generally felt really bad for about fourteen days - was mostly in bed. I didn't feel like doing anything. I maybe got a little energy back and I was able to drive. I didn't have a lot of stamina -and I'm like that to this very day. My left arm is very weak at times - tingly. I have to force myself to exercise every day. I ride my stationary bike for 10 minutes at a time and some days I walk for 10 minutes in my apartment. But some days I can't do it at all. Generalized weakness in especially in left arm and legs. This has been life changing for me. I walked 30 minutes every day before but after the vaccines, everything has changed me. Neurologist diagnosis now for Peripheral Neuropathy.  Wanted me to take Gabapentin for pain but I don't take it. If I do use anything I use Extra strength Tylenol. I started getting a rash between my breasts - right breast and right shoulder blade in my back. The pain shoots out from my spinal cord. I knew it was Shingles. I was vaccinated for that several years ago. I got the rash about three weeks ago. My doctor, PCP, put me on Anti-Viral - Acyclovir - I don't know if that helped me or not. I suffered with a lot of pain. It is a matter of it's running it's course. I still have pain from time to time. It was a really bad case - it kept me up at nights because of the pain. With the neuropathy, I had gone to ER - on June 3rd or June 6th - the doctor there had told me to go to a neurologist. I saw her within a couple of weeks after that.
Varicella vaccine was given prior to the 28 day interval mark after the MMR vaccine was administered.
Palpitations occurring 8 hours after shot. Constant chest pain and light headedness for two weeks, sometimes shortness of breath. 1 event of walking in a store and getting short of breath, heart racing and light headedness near the point of passing out. Shortness of breath doing any activity. Presumed case of myocarditis after bloodwork completed. Echocardiogram schedule 12/17 to confirm.
Information has been received via email from a consumer concerning her step sister who on an unspecified date was vaccinated with a dose of MMR II (dose, route and lot number not reported). The consumer reported that the step-sister's daughter suffered an allergic reaction, a fever of 106 and went into a coma after vaccination which resulted in brain damage and left her mentally disabled. At the time of the report the outcome of the patient was unknown. It was unspecified if the patient sought medical attention. Upon internal review, coma was determined to be an other important medical event. Mentally disabled and brain damage were considered to be disabling. Additional information has been requested.
A few weeks after receiving the Covid bivalent booster I developed severe tinnitus. It has slowly decreased since that time but is consistently what I would call mild to moderate tinnitus in both ears, left greater than right.
Patient experienced mild headache, resolved quickly (less than 30 mins) without intervention, evaluated by Nurse practitioner
HEART ATTACK; This spontaneous report received from a consumer via a company representative concerned a patient of unspecified age and sex via social media. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported. On an unspecified date, the patient experienced heart attack. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of heart attack was not reported. This report was serious (Other Medically Important Condition). This case, from the same reporter is linked to.; Sender's Comments: V0: -covid-19 vaccine ad26.cov2.s-heart attack. This event(s) is considered unassessable. The event(s) has an unknown/unclear temporal relationship, is unlabeled, and has unknown scientific plausibility. There is no information on any other factors potentially associated with the event(s).
circle around injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE REACTION (circle around injection site) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for an unknown indication.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On an unknown date, the patient experienced VACCINATION SITE REACTION (circle around injection site). At the time of the report, VACCINATION SITE REACTION (circle around injection site) outcome was unknown.            This case was linked to US-MODERNATX, INC.-MOD-2021-054963 (E2B Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-054963:Cross linked with second dose
cold; felt dizzy for short period; chills; Felt feverish; This spontaneous case was reported by a consumer and describes the occurrence of NASOPHARYNGITIS (cold), DIZZINESS (felt dizzy for short period), CHILLS (chills) and PYREXIA (Felt feverish) in an elderly patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001B21A) for COVID-19 prophylaxis.     Concurrent medical conditions included Drug allergy (aspirin).   On 13-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 13-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Aug-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced NASOPHARYNGITIS (cold), DIZZINESS (felt dizzy for short period), CHILLS (chills) and PYREXIA (Felt feverish). At the time of the report, NASOPHARYNGITIS (cold), DIZZINESS (felt dizzy for short period), CHILLS (chills) and PYREXIA (Felt feverish) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant products were not provided. Treatment medication were not reported.  It was reported that after 2nd primary dose felt dizzy for short period, vaccine was taken March 13,2021. Felt feverish/cold chills after taking booster shots, boosters were take November 13, 2021; August 10, 2022; and September 10 2022.   This case was linked to (Patient Link).
Left ovary pains. Numbness of right hand on palm and fingers. After 2nd shot, spotting and start of period after 6 years of menopause. Hot flashes started again after 4 years of ceasing.
This spontaneous report was received from a licensed practical nurse, regarding a 14 month old patient (gender not provided). Pertinent medical history and drug reactions/allergies were not provided. On 12-JUN-2013 the patient was vaccinated with a dose of PROQUAD (Merck) (route, lot number and expiration date were not provided). On the same date, the patient received a dose of VARIVAX (Merck), (route, lot number and expiration date were not provided). No adverse effect was reported. Additional information has been requested.
Information regarding Prevenar (pneumococcal 7-valent conjugate vaccine (diphtheria crm197 protein) injection) was received from a healthcare professional regarding a 6 year old male patient who experienced pneumococcal infection and drug ineffective. The patient received the third dose in Sept 2000 at 12 months of age. Relevant medical history was not provided. Indication for Prevnar was immunisation. Product was administered on 9/2000. Dose regimen was 1 dose 1 time per day intramuscular. Concomitant medications were not reported. In Sept 2000, at age 12 months of age, the patient received the third dose of Prevnar. On 11/20/2005, at 6 years of age, he developed pneumococcal infection, drug ineffective and was hospitalized. On 1/26/2006, a CSF culture positive revealed streptococcus pneumoniae, type E not 10,12. 33. The child recovered. No additional information was available at the time of this report.
COVID-19; COVID-19; This is a spontaneous report received from contactable reporter(s) (Physician). The reporter is the patient.  A 32-year-old female patient (not pregnant) received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), as dose 5 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "DM2" (unspecified if ongoing), notes: Other medical history: DM2; "hepatic adenomatosis" (unspecified if ongoing), notes: Other medical history: hepatic adenomatosis; "PCOS" (unspecified if ongoing), notes: Other medical history: PCOS; "depression" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: Treatment of COVID-19; (Jan2023) Negative; (Jan2023) Negative; (Jan2023) Negative. Therapeutic measures were taken as a result of drug ineffective, covid-19.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.; Sender's Comments: Based on the available information and close temporal association, a possible causal relationship cannot be excluded between the suspect vaccine BNT162b2 and the reported events "Drug ineffective", "COVID-19".
This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of DIABETES MELLITUS INADEQUATE CONTROL (Out of Control Blood Sugar (320 mg/dL)) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below. Concurrent medical conditions included Type 1 diabetes mellitus. Concomitant products included ROSUVASTATIN CALCIUM (CRESTOR) for Cholesterol, LOSARTAN for Prevention, INSULIN LISPRO (HUMALOG) for Type 1 diabetes mellitus. On 10-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-May-2021, the patient experienced INJECTION SITE PAIN (A little injection site pain). On 11-May-2021, the patient experienced DIABETES MELLITUS INADEQUATE CONTROL (Out of Control Blood Sugar (320 mg/dL)) (seriousness criteria medically significant). On 11-May-2021, INJECTION SITE PAIN (A little injection site pain) had resolved. At the time of the report, DIABETES MELLITUS INADEQUATE CONTROL (Out of Control Blood Sugar (320 mg/dL)) outcome was unknown. DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 10-May-2021, Blood glucose: slightly high blood glucose mg/dl (Inconclusive) Slightly high blood glucose. On 12-May-2021, Blood glucose: 320 mg/dl (High) High blood glucose. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. The night of vaccination, she had slightly high blood glucose, but it got worse as the days went by.  On 12-May-2021, her blood glucose reading was 320 mg/dl. It's high even when she is not eating. She increased her insulin dose triple fold to control her blood glucose. She called her Doctor and waited for him to call back. She stated that she had a very good control over her blood glucose. She knew that the uncontrolled blood glucose was caused by the vaccine. Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
I always receive vaccinations in my right arm. However, when I needed to receive a Hepatitis A/B combo vaccine on March 24, 2021 (5 days after the tdap vaccine) my right arm was in considerable pain, and I received the Hep vaccine in my left arm instead. I thought it was weird but wasn't overly worried. Within a few weeks, however, I noticed decreased range of motion and/or pain on performing certain tasks, including: putting on seatbelt, closing car door, reaching things from a shelf above shoulder height, shaving underarm, taking off and putting on shirt and bra, toweling dry after a shower, tying apron strings in back, wiping bottom, lifting arm straight up, putting things in right back pants pocket.
I was administering vaccine to patient and the needle was defective, and the plastic portion broke. Vaccine leaked out and the full dose was not administered (second dose in series). I called CDC for guidance and they advised reporting this event, and administering another dose immediately in the opposite arm. Patient had already left and I am waiting to hear back from her, but plan to administer vaccine again in opposite arm and have her wait for at least a half hour to observe for adverse reactions.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE HYPOXIA 2/14/2022 -- RECURRENCE OF SAME SYMPTOMS
Huge raised hive about the size of an apple maybe. Arm very sore/extremely itchy/hot feeling. Took Benadryl and applied ice. Hive lasted around 24 hours.
Follow-up information was received from a health care professional on 03 January 2012. Initial case received on 03 October 2011 was non-serious listed. Based on follow-up information the case has been changed to non-serious unlisted. This narrative contains information from both dates. This reporter also reported another adverse event that was captured in case number 2011-09657. A 68-year-old female patient had received a dose one intramuscular injection in the left deltoid of FLUZONE HIGH-DOSE, sanofi pasteur Inc., lot number UH459A on 30 September 2011. Following the vaccination, the patient experienced a rash on arm starting below the injection site to the elbow, red streaks from the injection site to 2-3 inches below the injection site and expanding to a "patch" of rash. The events lasted 4 to 5 days. No further information was available at the time of the report. The patient's outcome was reported as recovered on 10 December 2011. Documents held by sender: None.
Call from mother on day after immunization given. States pt left arm is red with questionable rash appearance and swollen. States the area is 4 inches in diameter and hot to the touch. States area encompasses both injection sites. Child will not allow anyone to touch it or put cool compress on it due to tenderness. Instructed mother to contact PMD.   still red on 05/15/2003  05/20/2003 update- swelling gone
This spontaneous case reported by a consumer, describes the occurrence of pyrexia (fever), fatigue (tiredness) and injection site erythema (redness at injection site) in an 83-year-old male patient who received mRNA-1273 (Moderna COVID-19 vaccine, batch# O41L20A) for COVID-19 immunization. The patient's past medical history included cardiac; pacemaker insertion. On Jan 13, 2021, patient received the first dose of mRNA-1273 (Moderna COVID-19 vaccine), intramuscular; 1 dosage form. On an unknown date, patient experienced pyrexia (fever), fatigue (tiredness) and injection site erythema (redness at injection site). At the time of the report, pyrexia (fever), fatigue (tiredness) and injection site erythema (redness at injection site) outcome: unknown/not provided. The action taken with mRNA-1273 (Moderna COVID-19 vaccine), intramuscular: unknown. Reporter's comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded. Further information requested.
tested positive of Covid-19 virus; became positive with covid between doses; This is a spontaneous report received from a contactable consumer (Patients wife) via contactable consumer reported similar events for 2 patients. This report is for 2nd of 2 patients. A male patient with unspecified units of age 49 received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Lot number and Expiration date was not reported), via an unspecified route of administration on an unspecified date as single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. It was reported that patient received first dose of BNT162B2. On last Wednesday (24Mar2021), the patient tested positive of COVID-19 virus. The patient became positive with COVID between doses of the Pfizer vaccine. The second dose of BNT162B2 is scheduled for 01Apr2021(coming Thursday); hence, the reporter wanted to know whether the second dose of BNT162B2 could be rescheduled. The outcome of the events was unknown.  Information on the lot/batch number has been requested; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021350996 same reporter/drug/event, different patient